[Treatment results in endometrial cancer in patients of reproductive age].
195 reproductive patients (23-29 years--6.2%, 40-45 years--57.4%) were treated for endometrial carcinoma. Stage I was detected in 64.4%, II--14.9%, III--8.7% and IV--3.1%. Well-differentiated cell adenocarcinoma was 3.1 times as frequent as light-cell, seroso-papillary, moderately-, low- and undifferentiated adenocarcinoma characterized by unfavorable clinical course. Overall 5-year survival was 89.8% (stage I--94.8%, II--78.6%, III-IV--69.7%).
Vishnevskaia
E E
EE
D000230:Adenocarcinoma / Q000628:therapy; D018262:Adenocarcinoma, Clear Cell / Q000628:therapy; D000328:Adult; D018283:Cystadenocarcinoma, Papillary / Q000628:therapy; D018284:Cystadenocarcinoma, Serous / Q000628:therapy; D016889:Endometrial Neoplasms / Q000473:pathology / Q000628:therapy*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome